PKM2 is a glycolytic enzyme that catalyzes the final step of glycolysis. In glioma cells, PKM2 predominantly exists in a less active dimeric form, leading to the accumulation of glycolytic intermediates that are diverted into biosynthetic pathways, supporting rapid tumor cell proliferation. This metabolic reprogramming is a hallmark of cancer cells, including gliomas.